SCHEMBL2925004

SCHEMBL2925004

Cc1ccc(-c2cccc(C(N)=O)c2CN2CCN(C)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.48
CHEK1 O14757 1/20 0.45
PARP2 Q9UGN5 3/20 0.44
PARP3 Q9Y6F1 1/20 0.44
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 2/20 0.42
GRM2 Q14416 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39
ITGB7 P26010 1/20 0.39
MEN1 O00255 1/20 0.39
KLK7 P49862 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KIT P10721 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924999 0.81 PARP1 (0.48) PARP1CHEK1PARP2PARP3ALDH1A1
SCHEMBL29817837 0.79 PARP1 (0.59) PARP1CHEK1PARP2PARP3LMNA
SCHEMBL28847349 0.75 KDM4E (0.49) PARP1CHEK1PARP2PARP3GAA
SCHEMBL16655571 0.75 ALDH1A1 (0.50) PARP1PARP2PARP3LMNAALDH1A1
SCHEMBL5482646 0.75 PPARG (0.45) PARP1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL16121663 0.75 CHKA (0.62) PARP1CHEK1PARP2PARP3
SCHEMBL28282551 0.72 BCAT2 (0.50) PARP1GAAALDH1A1GRM2KDM4E
SCHEMBL4878350 0.72 HDAC3 (0.55) PARP1PARP2PARP3LMNAALDH1A1
SCHEMBL6004326 0.70 BCAT2 (0.71) PARP1CHEK1LMNAGAATSHR
SCHEMBL31419622 0.68 BCAT2 (0.49) PARP1GAAALDH1A1GRM2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013035102-A1 PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF NATCO PHARMA LIMITED (IN) 2013-03-14 WO disclosed
EP-1833815-B1 A PROCESS FOR PREPARATION OF IMATINIB BASE INST FARMACEUTYCZNY (PL) 2010-09-15 EP disclosed
US-7674901-B2 Process for preparation of imatinib base INSTYTUT FARMACEUTYCZNY (PL) 2010-03-09 US disclosed
US-20080194819-A1 Process For Preparation of Imatinib Base INSTYTUT FARMACEUTYCZNY (PL) 2008-08-14 US disclosed
EP-1833815-A2 A PROCESS FOR PREPARATION OF IMATINIB BASE INSTYTUT FARMACEUTYCZNY (PL) 2007-09-19 EP disclosed
WO-2006071130-A2 A PROCESS FOR PREPARATION OF IMATINIB BASE INSTYTUT FARMACEUTYCZNY (PL) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194819-A1 Process For Preparation of Imatinib Base ABL1, ABL2, JAK2 PARP1 895/4885CHEK1 2204/4885PARP2 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.